MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
*Driving Forces: Market Research, Intelligence, Analysis, Datapoints, Databases & Trends
*Driving Forces: BioPharmaceuticals _ Biotechnology, Genomics, Genetics, Bioinformatics, Biomanufacturing & Personalized Medicine
*Driving Forces: Primary Care, Chronic Disease, Wellness, Weight Loss, Obesity, Coordinated Care
*Pioneers: Cardiology & Cardiovascular
Medical & Clinical Specialities
Diseases, Illnesses, Injury & Injuries
Depression
Parents
Amputation
Behavioral Health
Diseases, Illnesses, Injury & Injuries
Mental Health
Neuromodulation
Neurotechnology
Psychiatry & Psychology
TBI (Traumatic Brain Injury) & PTSD (Post Traumatic Stress Disorder)
Children
*Architects: Digital Health Information Technology
*Architects: Medical Imaging (MRI) Companies
*Architects: Neurology, Psychology, Mental Health, CNS, Pain & TBI Companies _ Depression, Anxiety Disorders, Schizophrenia, Etc
*Architects: Neurology, Psychology, Mental Health, CNS, Pain & TBI Companies _ PTSD, Suicide
*Architects: Neurology, Psychology, Mental Health, CNS, Pain & TBI Companies _ Sleep Medicine
*Architects: Neurology, Psychology, Mental Health, CNS, Pain & TBI Companies_Pain
*Architects: Obstetrics, Gynecology (OB/GYN) _ Women's Health, Maternal, Pregnancy, Menopause
*Architects: Schools & Universities (Mental Health, Counseling, COVID)
*Brain-Computer Interface company for treatment-resistant depression.
*Bright Minds has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain.
*Company is engaged the commercialization and distribution of OLEPTRO™ drug to treat depression among adults.
*Developing Mebufotenin 5-Methoxy-N, N-Dimethyltryptamine, or 5-MeO-DMT, therapies for the treatment of patients with Treatment-Resistant Depression, or TRD.
*Develops novel drugs for the treatment of diseases and disorders of the central nervous system - specifically, neuropsychiatric and neurological conditions such as schizophrenia, bipolar depression, and behavior disturbances associated with dementia
*Driving Forces: Neurology, Mental, Behavioral Health, Substance Abuse (SUD), Pain & Central Nervous System (CNS), Neurotechnology, Psychiatry and Psychology
*Funding: Complementary and Integrative Health
*Funding: Disease Management-Diseases & Conditions
*Funding: PCORI
*Industry: Houston
*Industry: Northern California & Silicon Valley
*INmune Bio (INMB) is a clinical-stage biopharma company that has a number of promising drugs in development that have the potential to address major problems like Alzheimer's and TRD (treatment-resistant depression).
*It develops drug candidates for the treatment of epilepsy, Parkinson's disease, conduct disorders, depression, anxiety, and attention-deficit/hyperactivity disorders.
*Marketing a device that uses repetitive transcranial magnetic stimulation (rTMS) to treat depression
*Neurotechnology applications are used to treat conditions such as Alzheimer’s disease, depression, obesity, stroke, epilepsy and chronic pain
*NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and PTSD.
*Offers research into many disorders such as lupus, eczema, diabetes, , depression, and muscular dystrophy
*Pioneers: Autism
*Pioneers: Geriatrics, Gerontology, Geroscience, Longevity, Healthspan & Aging
*Pioneers: Neurology, Neuroscience, Neurotechnology, Brain & CNS (Central Nervous System)
*Pioneers: Neuroscience
*Provide data and insights from the use of its low-intensity focused ultrasound to deliver neuromodulation therapy for chronic pain and depression.
*Talkiatry is an AI-powered virtual health platform that employs psychiatrists to provide anxiety, depression, insomnia, mood disorders, postpartum depression, children's mental health, bipolar disorder, OCD, PTSD and substance use disorder treatment.
*The ACCESS (Advancing Chronic Care with Effective, Scalable Solutions) Model tests an outcome-aligned payment approach in Original Medicare to expand access to new technology-supported care options that help people improve their health and prevent and manage chronic disease. The voluntary model focuses on conditions affecting more than two-thirds of people with Medicare, including high blood pressure, diabetes, chronic musculoskeletal pain, and depression. It will run for 10 years beginning July 5, 2026.
*The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain.
*The company’s first major initiative is developing psilocybin therapy for treatment-resistant depression (TRD), for which program they received FDA Breakthrough Therapy designation in 2018.
*The goal is to deliver stronger, targeted bursts of energy to specific areas of the brain on a patient-by-patient basis, to help reset the neural pathways that can drive the symptoms of depression.
2011: Brainsway wins Israeli nod for deep-brain stimulation device to treat depression (2011)
2012: Depression as recovery obstacle, mobile health’s evolution
2012: Maryland stem cell companies advance therapies for diabetes, depression (2012)
2014: J&J, Lundbeck spearhead an R&D consortium focused on depression, neurodegeneration
2015: GE Invests in Magnetic Brain Stimulation for Treating Depression...
2017: 23andMe to launch study exploring role of genetics in depression, bipolar disorders
2017: NIDA_Virtual Reality Framework for the study and treatment of depression (brand name or equal)
2017: VA_A--Research Post Partum Depression
2018: Alkermes Depression Drug Faces Long Odds After FDA Advisors Say No
2018: Alkermes: A Solid CNS Portfolio With An Option For Depression - Alkermes plc (NASDAQ:ALKS)
2018: CAPSTONE - Outcome Measure Harmonization and Data Infrastructure for Patient Centered Outcomes Research in Depression support.
2018: FDA Refuses Review of Alkermes Depression Drug, Wants More Trials
2018: Marinus Has A Long And Difficult Road Ahead In Postpartum Depression_seekingalpha.com
2018: NIDA_Virtual Reality Framework for Research and Treatment of Adolescence Depression
2019: AHRQ_CAPSTONE - Outcome Measure Harmonization and Data Infrastructure for Patient Centered Outcomes Research in Depression support
2019: Allergan’s $560M buyout deal just led to a PhIII debacle as another depression drug goes down to bitter defeat – Endpoints News
2019: Axsome sees in treatment-resistant depression study results in Q1_seekingalpha.com
2019: Intra-Cellular fingers a high placebo response explaining a PhIII failure as lead drug goes 1-and-1 in depression – Endpoints News
2019: Microcap biotech VistaGen turned to pennystock after PhII results show its depression drug doesn’t work solo – Endpoints News
2019: Sage_FDA approves trailblazing postpartum depression therapy, in crucial milestone for women’s health – Endpoints News
2020: Acadia Halts Work on Depression Drug After Late-Stage Trial Failure
2020: Intra-Cellular Therapies Announces Positive Topline Results from Study 402 Evaluating Lumateperone as Adjunctive Therapy in Patients with Bipolar Depression
2020: Neuronetics iTBS: Quick Electromagnetic Stimulation For Depression
2021: adyn’s first product, the Birth Control Optimization Test, is an at-home kit enabling users to collect both saliva and finger prick samples to measure hormone baseline levels and aims to assess genetic risk for blood clots and depression.
2021: AIM AHEAD_NIH Funds New Consortium Aimed at Advancing Health Equity and Researcher Diversity_University of North Texas Health Science Center
2021: Athenex: PDUFA This Week, Depressed Price, Likely Opportunity
2021: BioXcel Therapeutics: Ready To Enter The Depression Therapeutic Field
2021: Certified Community Behavioral Health Clinic (CCBHC) Grant Awards
2021: G1 Therapeutics: Depressed Price Post-Approval Presents Second Buying Opportunity_seekingalpha.com
2021: Magnus Medical debuts with $25M to target drug-resistant depression with personalized therapy
2021: Magnus Medical Launches With Breakthrough Device Designation for Rapid, Individualized Treatment of Major Depression and $25M in Series A Financing
2021: Meru Health develops digital mental health support program for employees with mild anxiety and depression
2021: NASEM Panel_DRUG RESEARCH AND DEVELOPMENT FOR ADULTS ACROSS THE OLDER AGE SPAN
2021: NCI_Using Information Technology to Support Systematic Screening and Treatment of Depression in Cancer (R21 Clinical Trial Optional)
2021: NHLBI_HEAL initiative: Pharmacotherapies to Reverse Opioid Overdose Induced Respiratory Depression Without Central Opioid Withdrawal (Target Validation and Candidate Therapeutic Development) (UG3/UH3 Clinical Trials Not Allowed)
2021: NIMH_Prevention of Perinatal Depression: Improving Intervention Delivery for At-Risk Individuals (R01 Clinical Trial Required)
2021: NIMH_Prevention of Perinatal Depression: Improving Intervention Delivery for At-Risk Individuals (R34 Clinical Trial Required)
2022: "Voice biomarker" tech analyzes your voice for signs of depression
2022: Adaptimmune Therapeutics: Depressed Despite Upcoming BLA_seekingalpha.com
2022: Developing proprietary deuterated psilocybin analog for the treatment of major depressive disorder (MDD)
2022: NIH Grant to Fund Study on mHealth App for Anxiety, Depression
2022: Northwell invests in Hume AI's nonverbal voice assessment with an eye toward understanding pain, depression
2022: Sage Therapeutics Could Be In For A Depressing FDA Review_ seekingalpha.com
2022: SAMHSA_RFI_SAMHSA's Role in Possible Agency Actions Regarding Mental Health and Substance Use Wellbeing in the Context of Climate Change and Health Equity
2022: UC Irvine receives $57.75 million for depression research, treatment
2022: With FDA approval, Axsome touts Auvelity as a potential game-changing depression treatment
2023: atai's Ketamine-Based Depression Candidate Falls Short in Phase II
2023: Eliem drops depression drug, ending pursuit of Biogen-Sage and laying off 55% of team
2023: Neumora: First Novel Mechanism Of Action Drug In Major Depression In Decades
2023: Sooma Medical’s neurostim device for at-home depression treatment lands FDA breakthrough tag
2024: Alto Neuroscience Reports Topline Results from a Phase 2b Trial Evaluating ALTO-100 as a Treatment for Major Depressive Disorder
2024: BrainsWay Is Reviving From A Deep Depression_seekingalpha.com
2024: College of Public Health receives NIH grant to pilot AI chatbot for African Americans with depression
2024: Insights into Molecular Basis of PTSD and Major Depression Could One Day Aid in Diagnosis and Treatment – NIH Director's Blog
2024: Intervention reduces likelihood of developing postpartum anxiety and depression by more than 70%
2024: NCI_NOSI: New Information Technology-Enabled Care Delivery Models to Improve Depression Care in Cancer
2024: Neumora Therapeutics' SWOT analysis: stock's potential in depression treatment market Investing.com
2024: NIMH_Precision Mental Health: Develop Tools to Inform Treatment Selection in Depression (UG3/UH3 Clinical Trial Optional)
2024: NIMH_Precision Mental Health: Develop Tools to Inform Treatment Selection in Depression (UG3/UH3 Clinical Trial Optional)
2024: NRx Pharma Advances FDA Application for Groundbreaking Ketamine Depression Treatment
2024: NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Files Initial Section of U.S. New Drug Application to the FDA for NRX-100 (IV Ketamine) for the Treatment of Suicidal Depression
2024: Supernus links depression drug to fast responses in ph. 2 trial
2024: Supernus’ depression drug improved symptoms in two hours in Phase IIa study
2025: Brain & Behavior Research Foundation (BBRF) announces recipients of 2025 Distinguished Investigator grants
2025: 10 clinical trials to watch in the first half of 2025
2025: AbbVie Smashes Earnings, Bets Big On Depression Drug Bretisilocin
2025: Alto misses primary efficacy endpoint in phase 2 depression trial
2025: America First Global Health Strategy
2025: Autolus Therapeutics Will Remain Depressed For A While
2025: Breakthrough Depression Treatment Reaches Critical Phase 3 Milestone: COMP360 Psilocybin Trial Fully Enrolled
2025: Fate Therapeutics: Suffering The Fate Of A Depressed Cell Therapy Sector
2025: Letter From the Director: Advancing AHRQ’s Mission
2025: Neumora Therapeutics Stock Crashes 81% After Depression Drug Flops
2025: Options shrink for Supernus depression drug candidate after key trial failure
2026: Announced late last year by the Center for Medicare and Medicaid Innovation, the ACCESS model will pay participants set rates to treat chronic conditions like diabetes, hypertension, high cholesterol, musculoskeletal pain, anxiety, and depression.
A user friendly app with music organized by mood and genre designed with research to directly correlated with the goal to decrease depression, anxiety, and any other mental health related issues.
Ahead is a platform that looks to help patients suffering from ADHD, depression and anxiety get the medical assistance they need through a combination of telehealth and in-person visits with providers
Aims to treat depression using a specific type of magnetic field found in some MRI imaging machines.
An interdisciplinary effort is underway to develop comprehensive understanding of energy production, metabolism, and oxygen use and to identify and control the protective mechanisms that preserve cellular function despite critically depressed oxygen delive
Architects: Neurology, Psychology, Mental Health, CNS, Pain & TBI Companies
Awarded multiple distinctions for novel AI technology through the National Science Foundation, Kintsugi detects signs of clinical depression and anxiety from short clips of free-form speech, closing mental health care gaps across risk-bearing health systems, saving time and lives.
Biogen Inc. (NASDAQ: BIIB)*
BrainCells Inc. had acquired the compound sabcomeline from London-based Proximagen, and planned to study the drug as a treatment for depression.
Brainsway Ltd (NASDAQ:BWAY)
By leveraging ongoing, passive monitoring, Mindstrong is able to capture digital biomarkers that serve as timely predictors of relapse in schizophrenia, bi-polar, ADHD, PTSD, clinical depression, and Substance Use Disorder, enabling intervention before conditions become chronic or severe.
clinical-stage pharmaceutical company focused on depression and other CNS-related disorders
Clinical-stage small molecule company focused on CNS disorders and depression, closed a $24M Series A financing (2010)
Depression
Depression
Depression and Anxiety treated with Choline analogs-Medical College of Georgia
depression as recovery obstacle, mobile health’s evolution
depression disease management program
depressive disorders, Alzheimer’s disease (AD) and Alzheimer’s disease-related dementias (ADRD), gender-based-violence), present and progress differently in women (e.g., cardiovascular disease
Developing novel voice biomarker infrastructure to detect signs of depression and anxiety from short clips of free form speech.
Ellipsis Health
Enables VA to better care for patients with chronic pain and/or depression by developing a system that allows nurse care managers to communicate regularly with Veterans online or on the phone for the remote management of Veterans’ chronic conditions.
Flow Neuroscience
Genetika+
GlobaLaseReach, Inc.
Henry M. Jackson Foundation for the Advancement of Military Medicine Inc. (HJF)
In-licensed three clinical-stage drug compounds that are being investigated for applications in general anesthesia, depression,
long lithium containing anti-depressants can up-regulate bel-2, a gene involved in apoptosis.
Mental Health Disorders (e.g., Depression)
Methods of Neuroendocrine Regulation to Treat Depression (BIDMC 169)-Beth Israel Deaconess Medical Center
Neuralstem stock jumps on FDA depression drug trial approval(2010)
Neuronascent is focused on the discovery and development of therapies for Alzheimer's disease, depression, and stroke based on t
Northern Illinois University_Feasibility of group versus individual self-management of depression using a mobile app, to increase treatment adherence among Dominican primary care patients (Dominican Republic)
Pharmacogenomics of Depression
Phyllis Foxworth Vice President of Advocacy, Depression and Bipolar Support Alliance (2020)
potential therapies for epilepsy, depression and post-traumatic stress disorder (PTSD) via TNS and for PTSD, obesity and cachexia via DBS.
Preclinical-stage biotechnology company focused on ADHD, depression, Parkinson’s and other CNS related diseases:Closed a $7.0M Series B financing (2011)
Preclinical-stage pharmaceutical company focused on depression
Prescription wearable device company pioneering the first hardware category to effectively compete with drug therapy for the treatment of depression, anxiety, and insomnia.
PureTech Ventures Launches Tal Medical To Develop Magnetic-Field Treatment for Depression (2011)
Reelin Diagnostic Test for Neuropsychiatric Disorders, including Schizophrenia, Autism, Depression, and Bipolar Disorder-University of Minnesota
RTM's respiratory monitor is a wearable, wireless, Bluetooth device that tracks key respiratory function indicators for respiratory depression/distress, physical fitness and early detection of heat exhaustion and heat stroke.
Serdaxin® a best-in-class therapy for treating depression, and potentially Parkinson’s Disease and Alzheimer’s Disease.
Software for early detection and assessment of depression-Harvard University Office of Technology Development
Sooma Medical
SSRI (selective serotonin reuptake inhibitors)
Swiss developer of deep brain stimulation implants for neurological indications such as Parkinson´s disease or depression
Tal Medical Gets NIMH Backing for Fast-Acting Depression Therapy (2014)
tDCS (Transcranial direct-current stimulation)
The 8 conditions and treatments are knee replacement, diabetes, heart failure, asthma, weight loss surgery, labor and delivery, spine surgery, and depression.
The company developed and markets the VNS Therapy System, which is FDA-approved for the treatment of refractory epilepsy and treatment-resistant depression. The VNS Therapy System uses an implanted medical device that delivers electrical pulsed signals to
The company launched autism care in April 2020 and has since expanded into developmental, attention behavior, anxiety, and mood disorders like autism, ADHD, OCD, depression, social anxiety, bipolarism, and more.
The company’s lead product candidate, EB-1010 for depression, is a triple reuptake inhibitor that acts on serotonin, norepinephrine and dopamine in a specific ratio and is given as monotherapy (a single capsule).
The company’s product uses machine learning to diagnose and track conditions such as Alzheimer's disease, Parkinson's, PTSD, and depression.
The purpose of this NOFO is to support the early stage testing of pharmacologic interventions with novel mechanisms of action or neuromodulatory device-based interventions for the treatment of symptoms or domains of altered functions in individuals with mental illness (e.g., schizophrenia, depression, autism, obsessive compulsive disorder, anxiety, bipolar disorder). Early intervention studies are also encouraged where symptoms of a disorder have been identified in subjects (a prodromal phase) prior to full diagnostic criteria being met. Ultimately, this NOFO is intended to support evaluation of pharmacologic or neuromodulatory device-based interventions using a protocol design where the presumed mechanism of action of the intervention is adequately tested, to provide meaningful information where target modulation yields a well-controlled, dose-dependent neurophysiological/clinical/behavioral effect.
The purpose of this phased Notice of Funding Opportunity (NOFO) is to create a pipeline to accelerate the development and early validation of predictive tools and/or biomarkers to inform individual-level treatment selection among two or more existing therapeutics for depression.
The purpose of this phased Notice of Funding Opportunity (NOFO) is to create a pipeline to accelerate the development and early validation of predictive tools and/or biomarkers to inform individual-level treatment selection among two or more existing therapeutics for depression. This phased inter-agency program will be milestone-based and provide support from multi-disciplinary teams to address scientific, technical, clinical, regulatory, and commercialization requirements. Ultimately, tools that are successful in early stage studies could be further evaluated for future use in decision-making in clinical practice settings.
The purpose of this program is to support a comprehensive public health and evidence-based approach that: (1) enhances behavioral health services for all college students, including those at risk for suicide, depression, serious mental illness (SMI)/serious emotional disturbances (SED), and/or substance use disorders that can lead to school failure
The purpose of this program is to support a comprehensive public health and evidence-based approach that: (1) enhances mental health services for all college students, including those at risk for suicide, depression, serious mental illness (SMI)/serious emotional disturbances (SED), and/or substance use disorders that can lead to school failure
TMS (Transcranial Magnetic Stimulation)
University of California San Francisco (UCSF)_Acceptability and Feasibility of Community-Based mHealth Motivational Interviewing Tool for Depression (COMMIT-D) to Improve Adherence to Treatment (Nepal)
uses MRIs to model where electrical current goes in the brain as a tool for placing a transmitter to moderate chronic pain and migraines or treat depression and other conditions. Read more: Federal dollars will give big boost to five med-tech companies in
Webicina Depression 2.0
Will depress share prices, the engine of biotech industry